

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oventus Medical Limited
ABN	12 608 393 282

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Melvyn John Bridges
Date of last notice	22 June 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Interests held by: Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust Parma Corporation Pty Ltd Lucille Bridges (spouse) Adinbri Super Pty Ltd atf The Bridges Super Fund
Date of change	7 August 2020

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>Direct: 75,367 Ordinary Shares; & 200,732 Options exercisable at \$0.578 ea, expiring 23 February 2021; & 50,000 Options at \$0.4228 ea, expiring 8 December 2024 Indirect – interests held by Parma Corporation Pty Ltd 1,587,595 Ordinary Shares & 58,674 Options at \$0.36 ea, expiring 30 June 2021 Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 474,276 Ordinary Shares & 3,295 Options at \$0.36 ea, expiring 30 June 2021 Indirect – interests held by Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 820,939 Ordinary Shares & 6,591 Options at \$0.36 ea, expiring 30 June 2021 Indirect – Lucille Bridges (spouse) 158,203 Ordinary Shares & 9,887 Options at \$0.36 ea, expiring 30 June 2021</p>
<p>Class</p>	<p>Options</p>
<p>Number acquired</p>	<p>Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 300,000 Options</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust Nil</p>

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p>Direct: 75,367 Ordinary Shares; & 200,732 Options exercisable at \$0.578 ea, expiring 23 February 2021; & 50,000 Options at \$0.4228 ea, expiring 8 December 2024</p> <p>Indirect – interests held by Parma Corporation Pty Ltd 1,587,595 Ordinary Shares & 58,674 Options at \$0.36 ea, expiring 30 June 2021</p> <p>Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 474,276 Ordinary Shares, 3,295 Options at \$0.36 ea, expiring 30 June 2021, & 300,000 Options at \$0.40 ea, expiring 7 August 2025</p> <p>Indirect – interests held by Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 820,939 Ordinary Shares & 6,591 Options at \$0.36 ea, expiring 30 June 2021</p> <p>Indirect – Lucille Bridges (spouse) 158,203 Ordinary Shares & 9,887 Options at \$0.36 ea, expiring 30 June 2021</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	Options issued as approved by Shareholders on 4 August 2020

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	
Interest acquired	
Interest disposed	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oventus Medical Limited
ABN	12 608 393 282

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sue MacLeman
Date of last notice	19 June 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Interests held by: Dalroar Pty Ltd (MacLeman Investment Trust)
Date of change	7 August 2020
No. of securities held prior to change	Direct: Nil Indirect: Interests held by Dalroar Pty Ltd (MacLeman Investment Trust): 54,132 Ordinary Shares 200,732 Options exercisable at \$0.578 ea, expiring 23 February 2021 50,000 Options at \$0.4228 ea, expiring 8 December 2024 988 Options at \$0.36 ea, expiring 30 June 2021
Class	Options
Number acquired	Direct – Nil Indirect: Dalroar Pty Ltd (MacLeman Investment Trust) 300,000 Options

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
No. of securities held after change	Direct: Nil Indirect: Interests held by Dalroar Pty Ltd (MacLeman Investment Trust): 54,132 Ordinary Shares 200,732 Options exercisable at \$0.578 ea, expiring 23 February 2021 50,000 Options at \$0.4228 ea, expiring 8 December 2024 988 Options at \$0.36 ea, expiring 30 June 2021 300,000 Options at \$0.40 ea, expiring 7 August 2025
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Options issued as approved by Shareholders on 4 August 2020

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

+ See chapter 19 for defined terms.

For personal use only

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oventus Medical Limited
ABN	12 608 393 282

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher Patrick Hart
Date of last notice	9 December 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Interests held by: C & L Super Pty Ltd as trustee for the Hart Superfund Larissa Diane Hart (spouse) as trustee for the Squirrel TST
Date of change	7 August 2020

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>Direct: 401,464 Options exercisable at \$0.578 ea; expiring 23 February 2021; 500,000 Options at \$0.4228 ea, expiring 8 December 2024; 70,000 Options at \$1.0628 ea, expiring 8 December 2024</p> <p>Indirect: Christopher Patrick Hart as trustee for the CHD (IP) Trust 26,126,513 Ordinary Shares</p> <p>Indirect: Interests held by C & L Super Pty Ltd as trustee for the Hart Superfund 40,000 Ordinary Shares</p> <p>Indirect: Larissa Diane Hart (spouse) as trustee for the Squirrel TST 376,000 Ordinary Shares</p>
<p>Class</p>	<p>Options</p>
<p>Number acquired</p>	<p>Direct – 5,000,000 Options</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small></p>	<p>Direct – Nil</p>
<p>No. of securities held after change</p>	<p>Direct: 401,464 Options exercisable at \$0.578 ea; expiring 23 February 2021; 500,000 Options at \$0.4228 ea, expiring 8 December 2024; 70,000 Options at \$1.0628 ea, expiring 8 December 2024; 5,000,000 Options at \$0.40 ea, expiring 7 August 2025</p> <p>Indirect: Christopher Patrick Hart as trustee for the CHD (IP) Trust 26,126,513 Ordinary Shares</p> <p>Indirect: Interests held by C & L Super Pty Ltd as trustee for the Hart Superfund 40,000 Ordinary Shares</p> <p>Indirect: Larissa Diane Hart (spouse) as trustee for the Squirrel TST 376,000 Ordinary Shares</p>

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Options issued as approved by Shareholders on 4 August 2020
--	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oventus Medical Limited
ABN	12 608 393 282

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sharad Joshi
Date of last notice	9 December 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	7 August 2020
No. of securities held prior to change	Direct – 201,139 Ordinary Shares; & 150,000 Options at \$0.4228 ea, expiring 8 December 2024
Class	Options
Number acquired	Direct – 300,000 Options
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	Direct – 201,139 Ordinary Shares, 150,000 Options at \$0.4228 ea, expiring 8 December 2024, & 300,000 Options at \$0.40 ea, expiring 7 August 2025
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Options issued as approved by Shareholders on 4 August 2020

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oventus Medical Limited
ABN	12 608 393 282

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Molloy
Date of last notice	19 June 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	7 August 2020
No. of securities held prior to change	Direct: 104,167 Ordinary Shares & 52,083 Options at \$0.36 ea, expiring 30 June 2021
Class	Options
Number acquired	Direct – 500,000 Options
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	Direct: 104,167 Ordinary Shares, 52,083 Options at \$0.36 ea, expiring 30 June 2021 & 500,000 Options at \$0.40 ea, expiring 7 August 2025
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options issued as approved by Shareholders on 4 August 2020

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oventus Medical Limited
ABN	12 608 393 282

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jake Nunn
Date of last notice	19 June 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	7 August 2020
No. of securities held prior to change	Direct: 156,250 Ordinary Shares & 78,125 Options at \$0.36 ea, expiring 30 June 2021
Class	Ordinary Shares & Options
Number acquired	Direct – 500,000 Options
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	Direct: 156,250 Ordinary Shares, 78,125 Options at \$0.36 ea, expiring 30 June 2021 & 500,000 Options at \$0.40 ea, expiring 7 August 2025
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options issued as approved by Shareholders on 4 August 2020

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

For personal use only